Transplant Complications Working Party (TCWP)
Study type:
Study number:
84110032
Type of Stem Cell Treatment:
Diseases:
Myelodysplastic (MDS) or MDS/MPN
Other myeloid or lymphoid malignancies
Short title:
Uric Acid Study
Primary objective:
To assess if uric acid acting as danger signal and released during conditioning therapy is associated with occurence and severity of acute GvHD
Key inclusion criteria:
First allo-SCT from HLA-matched sibling donors given stem cell grafts (bone marrow or peripheral blood) without T cell depletion, patients with AL, MDS or Lymphoma, Myeloablative and dose-reduced conditioning
Country:
Principal investigator:
Olaf Penack
EBMT Study coordinator:
Steffie van der Werf